Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (August 2025)
Shares of Pfizer ( NYSE: PFE ) lost 6.50% over the past month, bringing the stock's year-to-date loss to 11.31%.
Pfizer: Earnings Meet Pressure (Rating Upgrade)
Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth. Valuation appears attractive with ratios below ...
The 3 Things That Matter for Pfizer Now
Once a market darling during the early pandemic years, Pfizer (PFE 0.84%) has been on a straight southbound path for several years now. The company's shares are down by 50% since 2022.
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE:PFE) is set to announce its earnings on Tuesday, August 5, 2025, prior to the market opening. Analyzing Pfizer's stock performance over the previous five years after earnings announcem...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pfizer's Comeback Is Underway
Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Me...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Med...
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Pfizer: Building The Next Oncology Empire
$43Bn Seagen acquisition positions Pfizer to dominate the $140Bn antibody-drug conjugate market. Numerous potential blockbusters launching pre-2030 should strengthen its oncology portfolio to offse...
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
One of the big reasons to like Pfizer (PFE -0.47%) today is its huge 7.1% dividend yield. To put that yield into context, the S&P 500 index is yielding roughly 1.3% and the average healthcare stock...
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass ...
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatme...
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Related Companies